Effectiveness of Cranberry Ingestion on Bacterial Adhesion: An Adjunct Study
NCT ID: NCT00506025
Last Updated: 2017-12-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
51 participants
INTERVENTIONAL
2006-08-31
2008-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The reviewers of our proposal enumerated specific weaknesses including 1) a need to evaluate urine from cranberry treated patients, and 2) consideration of bacterial virulence/adherence. The additional variable of gestational diabetes also received comment from the reviewers, and we acknowledge that predisposition in the Hispanic population to this obstetrical complication could impact results. A constituent of cranberries is fructose, which has been implicated in the inhibition of E. coli with type 1 fimbriae (mannose-sensitive) (2). We hypothesize that the glucosuria associated with diabetes in pregnancy may influence the effectiveness of cranberry to prevent asymptomatic bacteriuria.
We must address these weaknesses to strengthen chances for continued funding and competitive renewal.
We have made inquiries with other researchers, and have discovered no direct urine or serum assays by which to measure cranberry metabolites. We understand that there is an R21 proposal under consideration to develop a urinary assay for this purpose under the same RFA. Amy Howell, PhD, of the Marucci Center for Blueberry/Cranberry Research of Rutgers University, one of the field's foremost researchers in this field, and others have indirectly assayed compliance to cranberry by evaluating adherence of piliated E. coli strains before and after cranberry exposure (1). In response to the recent call for proposals for faculty research from the UCI Committee on Research, I proposed this pilot study in collaboration with Dr. Howell.
In this proposal, we will collect the urine from various participants in the R21 trial so as to characterize the effect of cranberry juice ingestion on bacterial adherence. We will ask women to collect their urine for a four-hour time period including first-morning void. The urine samples will be sent to Dr. Howell's laboratory at Rutgers University for analysis. We will collect urine from pregnant women who are assigned to cranberry and to placebo, and from those women who develop bacteriuria following cranberry and following placebo ingestion. We also plan to identify a group of reproductive age, healthy, and non-pregnant women to ingest the active cranberry product or placebo for three days, and on the third day, collect a four-hour timed sample in the same manner as the pregnant women in our control group.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
FACTORIAL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cranberry 2xday
Cranberry juice (C) two times daily, a.m. and p.m.
Cranberry Juice
Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
Cranberry + Placebo
De-Activated Cranberry juice in the am, then placebo (P) in the pm
Cranberry Juice
Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
Placebo 2xday
Placebo in the form of juice two times daily in the a.m. and p.m.
De-Activated Cranberry juice
De-Activated Cranberry juice in the am, then placebo (P) in the pm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cranberry Juice
Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
De-Activated Cranberry juice
De-Activated Cranberry juice in the am, then placebo (P) in the pm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented fetal viability (either by fetal heart tones present by Doppler auscultation, or by ultrasonic visualization of cardiac motion
* Estimated gestational age by last menstrual period and/or by ultrasonographic fetal measurements of 16 weeks or less
Exclusion Criteria
* Patient desires pregnancy termination
* Significant underlying medical complication, such as chronic hypertension, insulin-requiring diabetes, chronic renal failure, cardiac disease, sickle cell disease, etc.
* Maternal age less than 18 years
* Patient is currently on or has received within the two weeks prior to enrollment antimicrobial therapy for reasons other than urinary tract infection.
18 Years
45 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Irvine
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Deborah A. Wing
Director, Division of Maternal-Fetal Medicine, Obstetrics & Gynecology, University of California, Irvine School of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Deborah A Wing, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, Irvine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Irvine Medical Center
Orange, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2006-4896
Identifier Type: -
Identifier Source: org_study_id